Overview

Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

Status:
Withdrawn
Trial end date:
2011-01-01
Target enrollment:
0
Participant gender:
All
Summary
This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Pfizer
Treatments:
Rifampin
Sitaxsentan
Criteria
Inclusion Criteria:

- Healthy male subjects and/or women of non-child bearing potential.

- Subjects between the ages of 21 and 55 years, inclusive.

- Signed informed consent.

Exclusion Criteria:

- Evidence or history of clinically significant hematological, renal, endocrine,
pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
allergic disease.

- Has hepatic dysfunction.

- Has history of excessive alcohol and tobacco use.